Accelerate Diagnostics Inc Revenue Growth Rates (AXDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Accelerate Diagnostics Inc   (NASDAQ: AXDX)
 

AXDX's Revenue Growth by Quarter and Year

Accelerate Diagnostics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AXDX Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 2.82
3rd Quarter September 2.86
2nd Quarter June 2.68
1st Quarter March 2.72
FY 11.08

AXDXs Annual Revenue
Accelerate Diagnostics Inc 's Revenue in the fiscal year 2024 $ 10.70 millions
Accelerate Diagnostics Inc 's Revenue in the fiscal year 2023 $ 3.55 millions
Accelerate Diagnostics Inc 's Revenue in the fiscal year 2022 $ 12.75 millions
Accelerate Diagnostics Inc 's Revenue in the fiscal year 2021 $ 16.28 millions
Accelerate Diagnostics Inc 's Revenue in the fiscal year 2020 $ 11.17 millions




AXDX Revenue fourth quarter 2024 Y/Y Growth Comment
Accelerate Diagnostics Inc reported decrease in Revenue in the fourth quarter 2024 by -7.06% to $ 2.82 millions, from the same quarter in 2023.
The decrease in the fourth quarter 2024 Accelerate Diagnostics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 279.81%.

Looking into fourth quarter 2024 results within Laboratory Analytical Instruments industry 15 other companies have achieved higher Revenue growth. While Accelerate Diagnostics Inc ' s Revenue decline of -7.06% ranks overall at the positon no. 3340 in the fourth quarter 2024.


AXDX Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December -7.06 % 2.02 % -11.08 % 7.4 %
3rd Quarter September 157.66 % -62.5 % -5.13 % -13.09 %
2nd Quarter June -4.29 % -27.46 % 37.86 % 31.46 %
1st Quarter March -3.2 % -5.07 % 17.46 % 7.69 %
FY   13.6 % -23.53 % 8.23 % -

Financial Statements
Accelerate Diagnostics Inc 's fourth quarter 2024 Revenue $ 2.82 millions AXDX's Income Statement
Accelerate Diagnostics Inc 's fourth quarter 2023 Revenue $ 3.03 millions Quarterly AXDX's Income Statement


AXDX Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December -1.54 % 172.97 % 0.34 % 7.05 %
3rd Quarter September 6.72 % -60.36 % -23.32 % 11.43 %
2nd Quarter June -1.47 % -0.36 % 30.41 % 11.11 %
1st Quarter March -10.23 % -5.39 % -11.38 % -18.97 %
FY (Year on Year)   13.6 % -23.53 % 8.23 % -


Back to AXDX Growth rate Comparisons >> Back to AXDX Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #437
Overall #3340

Revenue Y/Y Growth Statistics
High Average Low
9138.46 % 279.81 % -96.56 %
(Jun 30 2018)   (March 31, 2014)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #16
Healthcare Sector #437
Overall #3340
Revenue Y/Y Growth Statistics
High Average Low
9138.46 % 279.81 % -96.56 %
(Jun 30 2018)   (March 31, 2014)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Accelerate Diagnostics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1523.19 % 95.81 % -96.13 %
(Jul 31 2012)  


AXDX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Accelerate Diagnostics Inc disclosed decrease in Revenue from the third quarter by -1.54% to $ 2.82 millions, from $ 2.86 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Laboratory Analytical Instruments's company achievement, Most analysts pointed out.

Within Laboratory Analytical Instruments industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Accelerate Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 3276.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #22
Healthcare Sector #491
Overall #3276
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #22
Healthcare Sector #491
Overall #3276
Revenue Q/Q Growth Statistics
High Average Low
1523.19 % 95.81 % -96.13 %
(Jul 31 2012)  


AXDX's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Accelerate Diagnostics Inc disclosed decrease in Revenue from the third quarter by -1.54% to $ 2.82 millions, from $ 2.86 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Laboratory Analytical Instruments's company achievement, Most analysts pointed out.

Within Laboratory Analytical Instruments industry 21 other companies have achieved higher Revenue quarter on quarter growth. While Accelerate Diagnostics Inc 's Revenue growth quarter on quarter, overall rank is 3276.


Accelerate Diagnostics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)
Cumulative Revenue 12 Months Ending $ 11.07 $ 11.28 $ 9.53 $ 9.66 $ 9.75
Y / Y Revenue Growth (TTM) 13.61 % 16.42 % -17.42 % -23.4 % -23.58 %
Year on Year Revenue Growth Overall Ranking # 3335 # 2915 # 2820 # 2707 # 2782
Seqeuential Revenue Change (TTM) -1.87 % 18.35 % -1.27 % -0.91 % 0.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 2196 # 2588 # 1658 # 1659 # 2875


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2024 period, Accelerate Diagnostics Inc 's cumulative twelve months Revenue were $ 11 millions, company would post below average annual Revenue growth of 0.56% year on year, if the fiscal year would end at Dec 31 2024.
A slow-down in the Accelerate Diagnostics Inc 's Revenue growth from the 2.86% growth in Sep 30 2024.

In the Healthcare sector 444 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2915 to 3335.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 11
Healthcare Sector # 445
Overall # 3335

Revenue TTM Y/Y Growth Statistics
High Average Low
2593.5 %
 196.65 %
-81.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 336
S&P 500 # 2196
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2024 period, Accelerate Diagnostics Inc 's cumulative twelve months Revenue were $ 11 millions, company would post below average annual Revenue growth of -81.47% year on year, if the fiscal year would end at Dec 31 2024.
A slow-down in the Accelerate Diagnostics Inc 's Revenue growth from the 2.86% growth in Sep 30 2024.

In the Healthcare sector 444 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2915 to 3335.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 11
Healthcare Sector # 445
Overall # 3335

Revenue TTM Y/Y Growth Statistics
High Average Low
2593.5 %
196.65 %
-81.47 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 336
S&P 500 # 2196




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AXDX's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Accelerate Diagnostics Inc Revenue Growth Rates (AXDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Accelerate Diagnostics Inc (CIK 727207).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-014205
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Accelerate Diagnostics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.